IL13 and allergic asthma: BM-MSCs preconditioned with EPA decreased BALF inflammatory cell counts, levels of TH2 cytokines (IL-4 and IL-13), lung fibrosis, and the presence of mucus-producing cells, and improved lung function in experimental HDM-induced allergic asthma (Abreu et al., 2018).